We are a biopharmaceutical company devoted to the development of a new class of therapeutics to address unmet medical needs in cancer.
Libera Bio aims at changing cancer therapy by allowing biologics to cross the cell membrane and reach “undruggable” intracellular targets: the “Holy Grail” in oncology
Libera Bio leverages its unique proprietary nanotechnology to hold and protect biologicals (e.g., antibodies) in the blood stream following IV administration and to deliver them intracellularly to tumor cells and to metastatic cells
Libera Bio seeks to maximize the use of its technology with oncology biopharma partners, to offer patients new oncology breakthrough treatments based on intracellular delivery of biologics
Discover our MPN Technology®
Our patented MPN Technology® enables the discovery and development of new compounds involving intracellular biologics, especially monoclonal antibodies (mAbs), to successfully engage previously undruggable targets.
Libera Bio lead target is Mutated KRAS:
KRAS is the Most Frequently Mutated Gene in Human Cancer (e.g. in 9 out of 10 Pancreatic Ductal Adenocarcinoma – PDAC)
The presence of mutant KRAS is associated with poor prognosis and resistance to chemotherapy and targeted treatments (e.g. EGFR)
Despite this important Unmet Medical Need, the development of effective anti-RAS therapies has been marred by more than three decades of failure
Libera Bio is open to licensing or partnering its MPN Technology® to develop or co-develop new cancer treatments based either on biologics or small molecules.
Partnering contact: Olivier Jarry, email@example.com
Inquiries from potential investors in the next round of funding of Libera Bio are welcome.
Investors Relations: firstname.lastname@example.org
Persoal cofinanciado pola Xunta de Galicia ao abeiro da Resolución da Axencia Galega de Innovación do 29 de xullo de 2021 (Programa Talento Sénior)
Avenida do Mestre Mateo 2
15706 Santiago de Compostela, A Coruña (Spain)
15 Rockridge Rd
Larchmont NY 10538-3918